Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has earned a consensus recommendation of “Buy” from the six research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $26.00.
A number of research firms recently weighed in on AGLE. Zacks Investment Research cut Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. ValuEngine raised Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 5th.
Shares of AGLE traded down $0.05 during mid-day trading on Monday, reaching $8.51. The company had a trading volume of 57,543 shares, compared to its average volume of 97,613. Aeglea Bio Therapeutics has a twelve month low of $5.12 and a twelve month high of $12.00. The stock has a market cap of $207.03 million, a PE ratio of -4.73 and a beta of 0.86.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.10). Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 62.12%. As a group, analysts anticipate that Aeglea Bio Therapeutics will post -1.86 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in AGLE. Cubist Systematic Strategies LLC acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter valued at $131,000. Rhumbline Advisers acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter valued at $161,000. AQR Capital Management LLC increased its holdings in Aeglea Bio Therapeutics by 42.0% during the 3rd quarter. AQR Capital Management LLC now owns 28,297 shares of the biotechnology company’s stock valued at $271,000 after purchasing an additional 8,376 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter valued at $321,000. Finally, Bank of New York Mellon Corp acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter valued at $438,000. 61.13% of the stock is owned by hedge funds and other institutional investors.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
See Also: What is a stock buyback?
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.